NanoVibronix, Inc. Files Amendment to Annual Report (10-K/A)

TL;DR

<b>NanoVibronix, Inc. has filed an amendment to its 2023 annual report, providing updated information for its common stock traded on NASDAQ.</b>

AI Summary

NanoVibronix, Inc. (FEED) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. NanoVibronix, Inc. filed an amendment (No. 2) to its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive office is located in Tyler, Texas. NanoVibronix, Inc. is registered under the SIC code 3842 for Orthopedic, Prosthetic & Surgical Appliances & Supplies. The company's common stock, par value $0.001 per share, is registered under the trading symbol NAOV on the NASDAQ Capital Market. The filing indicates that NanoVibronix, Inc. is a non-accelerated filer and has submitted all required reports for the preceding 12 months.

Why It Matters

For investors and stakeholders tracking NanoVibronix, Inc., this filing contains several important signals. This amendment to the 10-K filing may contain updated financial information, business descriptions, or risk factors that could impact investor understanding of the company's current standing. As a non-accelerated filer, the company's reporting obligations and disclosures may differ from larger, more actively traded companies, which is important for investors to note.

Risk Assessment

Risk Level: low — NanoVibronix, Inc. shows low risk based on this filing. The risk is low as this is an amendment to a routine annual filing and does not appear to indicate any immediate material adverse events based on the provided header information.

Analyst Insight

Investors should review the full amended 10-K filing to understand any changes or updates to NanoVibronix, Inc.'s financial position, business operations, and risk disclosures.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the annual report)
• 001-36445 — Commission File Number (SEC file number for NanoVibronix, Inc.)
• NAOV — Trading Symbol (Symbol for NanoVibronix, Inc. common stock)
• $0.001 — Par Value (Par value of the company's common stock)

Key Players & Entities

• NanoVibronix, Inc. (company) — Registrant name
• NASDAQ Capital Market (company) — Exchange where common stock is registered
• NAOV (company) — Trading symbol for common stock
• 001-36445 (regulator) — Commission File Number
• 20231231 (date) — Fiscal year end
• 20240426 (date) — Filing date

FAQ

Industry Context

NanoVibronix, Inc. operates in the medical devices sector, specifically within orthopedic, prosthetic, and surgical appliances and supplies.

Regulatory Implications

The company is subject to SEC reporting requirements under the Securities Exchange Act of 1934, including the filing of annual reports on Form 10-K.

What Investors Should Do

1. Review the full amended 10-K filing for detailed financial statements and operational updates.
2. Analyze any changes in risk factors or business descriptions provided in the amendment.
3. Monitor future filings for ongoing company performance and disclosures.

Key Dates

• 2023-12-31: Fiscal Year End — The period for which the annual report is filed.
• 2024-04-26: Filing Date — Date the amendment to the 10-K was filed with the SEC.

Year-Over-Year Comparison

This is an amendment (No. 2) to the previously filed 10-K for the fiscal year ended December 31, 2023, indicating updates or corrections to the original filing.

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share NAOV NASDAQ Capital Mark
• $1.5 billion — Tax at Kinetic Concepts, Inc. ("KCI") a $1.5 billion MedTech company, which was recently pur
• $6.7 billion — which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number

Filing Documents

• form10-ka.htm (10-K/A) — 315KB
• ex31-1.htm (EX-31.1) — 7KB
• ex31-2.htm (EX-31.2) — 7KB
• form10-ka_001.jpg (GRAPHIC) — 5KB
• 0001493152-24-016463.txt (&nbsp;) — 601KB
• naov-20231231.xsd (EX-101.SCH) — 3KB
• naov-20231231_lab.xml (EX-101.LAB) — 36KB
• naov-20231231_pre.xml (EX-101.PRE) — 24KB
• form10-ka_htm.xml (XML) — 7KB

Executive Compensation

Executive Compensation 13 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 18 Item 13 Certain Relationships and Related Transactions, and Director Independence 21 Item 14 Principal Accountant Fees and Services 22 PART IV Item 15 Exhibits and Financial Statement Schedules 23

Signatures

Signatures 24 4 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE Board of Directors The following table sets forth the name, age and positions of each director as of the filing date of this Amendment No. 2. Name Age Position with the Company Brian Murphy 67 Chief Executive Officer and Director Harold Jacob, M.D. 69 Chief Medical Officer and Director Christopher Fashek(3) 74 Chairman of the Board Martin Goldstein, M.D.(3) 56 Director Michael Ferguson(1)(2) 53 Director Thomas R. Mika(1)(2) 72 Director Aurora Cassirer(1)(3) 72 Director Maria Schroeder(2)(3) 65 Director (1) Current member of Compensation Committee. (2) Current member of Audit Committee. (3) Current member of Nominating and Corporate Governance Committee. The following sets forth biographical information and the qualifications and skills for each director: Brian Murphy, Chief Executive Officer and Director . Mr. Murphy has served as our chief executive officer and director since October 2016. Mr. Murphy has over 25 years of senior sales, operations and general management experience in medical device and medical technology companies, including ATI Medical Equipment Corporation, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc. From 2012 to 2016, Mr. Murphy served in various roles at MiMedx Group, Inc., where he initiated and managed the commercial sales and national accounts efforts within the advanced wound care segment. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc., a start-up wound care diagnostics company, and led the sale of the company to Systagenix Ltd. in June 2012. From 2008 to 2010, Mr. Murphy served as vice president of sales for ConvaTec and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served a total of 17 years at Kinetic Concepts, Inc. (KCI) in various positions overseeing sales, operations and general manag

View Full Filing

View this 10-K/A filing on SEC EDGAR